Metastatic Prostate Cancer [clinicaltrials_resource:027e520d82ce08bd9b2430af6dd75f14]
PROSTACOX : Metastatic Prostate Chemotherapy [clinicaltrials:NCT00213694]Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy [clinicaltrials:NCT00216060]CMAB vs IMAB in Metastatic Prostate Cancer [clinicaltrials:NCT00255268]ZANTE: Zometa and Taxotere in Hormone Refractory Prostate Cancer [clinicaltrials:NCT00415779]clinicaltrials:NCT00439270Safety Study of a Radiolabeled Antibody (7E11) in Patients With Progressive Hormone Refractory Prostate Cancer [clinicaltrials:NCT00441571]clinicaltrials:NCT00452387Phase II Trial of Docetaxel and Celecoxib in Patients With Androgen Independent Prostate Cancer [clinicaltrials:NCT00494338]Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer [clinicaltrials:NCT00541281]Phase II Sunitinib Prog Met AIPC [clinicaltrials:NCT00599313]clinicaltrials:NCT00638378clinicaltrials:NCT00942578Docetaxel With a Phytochemical in Treating Patients With Hormone Independent Metastatic Prostate Cancer [clinicaltrials:NCT01012141]Duration of Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Men With Metastatic CRPC [clinicaltrials:NCT01062503]Human Telomerase Reverse Transcriptase Messenger RNA (hTERT mRNA) Transfected Dendritic Cell Vaccines [clinicaltrials:NCT01153113]Biomarkers of Bone Resorption in Metastatic Prostate Cancer [clinicaltrials:NCT01233557]clinicaltrials:NCT01303705clinicaltrials:NCT01558219Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer [clinicaltrials:NCT01560923]clinicaltrials:NCT01677897The Association Between Alpha 1 Acid Glycoprotein Level and Outcome Metastatic Cancer Treated With Docetaxel [clinicaltrials:NCT01814150]Evaluation of 18F-DCFBC PSMA-based PET Imaging for Detection of Metastatic Prostate Cancer [clinicaltrials:NCT01815515]clinicaltrials:NCT01923727clinicaltrials:NCT01933022A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer [clinicaltrials:NCT01981122]clinicaltrials:NCT02036060Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer [clinicaltrials:NCT02049190]Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks [clinicaltrials:NCT02051218]A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostrate Cancer and Men With Metastatic Prostate Cancer [clinicaltrials:NCT02066961]A Safety Study of 18F-DCFPyL, a PSMA-based PET Radiotracer, in Patients With Advanced Prostate Cancer [clinicaltrials:NCT02151760]Prospective Evaluation of Stereotactic Body Radiotherapy for Metastatic Prostate Cancer [clinicaltrials:NCT02206724]clinicaltrials:NCT02260817clinicaltrials:NCT02278055Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC) [clinicaltrials:NCT02380274]clinicaltrials:NCT02500901
condition [clinicaltrials_vocabulary:condition]
Metastatic Prostate Cancer [clinicaltrials_resource:027e520d82ce08bd9b2430af6dd75f14]
Bio2RDF identifier
027e520d82ce08bd9b2430af6dd75f14
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:027e520d82ce08bd9b2430af6dd75f14
identifier
clinicaltrials_resource:027e520d82ce08bd9b2430af6dd75f14
title
Metastatic Prostate Cancer
@en
label
Metastatic Prostate Cancer [clinicaltrials_resource:027e520d82ce08bd9b2430af6dd75f14]
@en